quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:32:43·20d
SECFiling
Krystal Biotech Inc. logo

SEC Form DEFA14A filed by Krystal Biotech Inc.

KRYS· Krystal Biotech Inc.
Health Care
Original source

Companies

  • KRYS
    Krystal Biotech Inc.
    Health Care

Recent analyst ratings

  • Mar 27UpdateWolfe Research-
  • Jan 6UpdateCitigroup$309.00
  • Mar 5UpdateJefferies$245.00
  • Aug 6UpdateCitigroup$204.00
  • Nov 20UpdateGoldman$160.00
  • Oct 24UpdateCantor Fitzgerald$100.00

Related

  • PR2d
    Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
  • SEC20d
    SEC Form DEF 14A filed by Krystal Biotech Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.
  • ANALYST27d
    Wolfe Research initiated coverage on Krystal Biotech
  • PR31d
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
  • INSIDER48d
    New insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)
  • INSIDER48d
    New insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)
  • INSIDER48d
    President, R&D Krishnan Suma sold $6,580,270 worth of shares (25,000 units at $263.21), decreasing direct ownership by 2% to 1,403,155 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022